(ABLD) AbL Diagnostics - Ratings and Ratios

Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR001400AHX6

Description: ABLD AbL Diagnostics

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. It offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S RNA; ultragene assays for viral detection of SARS CoV-2, dengue, and Zika virus; microbiological specimen transport and collection kits, which include RNA and saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation system, and sanger sequencing reagents. The company also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB. It sells its products directly, as well as through a network of distributors to academic clinical pathology labs, private reference labs, and researchers. The company was formerly known as Etablissements Fauvet Girel and changed its name to ABL Diagnostics Société anonyme in April 2022. The company is based in Woippy, France. ABL Diagnostics Société anonyme is a subsidiary of Advanced Biological Laboratories (ABL) S.A., Web URL: https://www.abldiagnostics.com

Additional Sources for ABLD Stock

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

ABLD Stock Overview

Market Cap in USD 103m
Sector Healthcare
Industry Health Information Services
GiC Sub-Industry Health Care Technology
IPO / Inception

ABLD Stock Ratings

Growth Rating 30.0
Fundamental -
Dividend Rating 1.0
Rel. Strength 111
Analysts -
Fair Price Momentum 5.68 EUR
Fair Price DCF -

ABLD Dividends

Dividend Yield 12m 1.21%
Yield on Cost 5y 1.17%
Annual Growth 5y %
Payout Consistency 1.0%
Payout Ratio %

ABLD Growth Ratios

Growth Correlation 3m -60.7%
Growth Correlation 12m 79.3%
Growth Correlation 5y 35%
CAGR 5y 12.32%
CAGR/Max DD 5y 0.14
Sharpe Ratio 12m -0.09
Alpha 89.13
Beta 0.355
Volatility 11.37%
Current Volume 0.1k
Average Volume 20d 0k
Stop Loss 5.3 (-2.8%)
What is the price of ABLD shares?
As of July 15, 2025, the stock is trading at EUR 5.45 with a total of 105 shares traded.
Over the past week, the price has changed by +1.87%, over one month by +0.93%, over three months by -0.89% and over the past year by +96.45%.
Is AbL Diagnostics a good stock to buy?
Neither. Based on ValueRay´s Analyses, AbL Diagnostics is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 30.02 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABLD is around 5.68 EUR . This means that ABLD is currently overvalued and has a potential downside of 4.22%.
Is ABLD a buy, sell or hold?
AbL Diagnostics has no consensus analysts rating.
What are the forecasts for ABLD share price target?
According to our own proprietary Forecast Model, ABLD AbL Diagnostics will be worth about 6.3 in July 2026. The stock is currently trading at 5.45. This means that the stock has a potential upside of +15.23%.
Issuer Target Up/Down from current
Wallstreet Target Price 6 10.3%
Analysts Target Price - -
ValueRay Target Price 6.3 15.2%